Skip to main content

Altimmune, Inc 8-K, filed Nov 12, 2026

Altimmune, Inc. (ALT)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Altimmune, Inc filed this 8-K on November 12, 2026.

Altimmune reported $480 million in cash, cash equivalents and investments as of September 30, 2026, and a net loss of $31.6 million, or $0.15 per share. PERFORMA Phase 3 progressed as planned, and an FDA End-of-Phase 2 meeting for AUD was scheduled for December 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits